Wave Life Sciences Initiates Phase 2a INLIGHTâ„¢ Trial of WVE-007 for Obesity and Cardiometabolic Diseases
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
